Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.17.20 extracted from

  • Brouns, R.; Heylen, E.; Sheorajpanday, R.; Willemse, J.L.; Kunnen, J.; De Surgeloose, D.; Hendriks, D.F.; De Deyn, P.P.
    Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients (2009), Clin. Neurol. Neurosurg., 111, 165-170.
    View publication on PubMed
Search for more literature for 3.4.17.20

Application

Application Comment Organism
medicine proCPU activation and its relatedness to efficacy and safety of thrombolytic therapy in ischemic stroke patients is investigated. In 12 patients with ischemic stroke who are treated with intravenous or intraarterial thrombolysis, venous blood samples are taken at different time points before, during and after thrombolytic therapy. No correlations between maximal CPU activity or proCPU consumption and patient or stroke characteristics are found. Maximal CPU activity is associated with evolution of the clinical deficit and achieved recanalisation. ProCPU consumption is related to the risk of intracranial hemorrhage, mortality and final infarct volume Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
 Homo sapiens
-

Synonyms

Synonyms Comment Organism
carboxypeptidase U
-
 Homo sapiens
CPU
-
 Homo sapiens
TAFIa
-
 Homo sapiens
thrombin-activatable fibrinolysis inhibitor
-
 Homo sapiens